TABLE 1.
Baseline characteristics of matched 164 cancer patients with COVID‐19 versus 164 cancer control patients without COVID‐19
| Characteristic | Categories/summary statistic | COVID‐19 N (%) | Control N (%) | p |
|---|---|---|---|---|
| Age (years) | Mean (standard deviation) | 59.2 (15.4) | 60.4 (16.8) | 0.510 |
| Sex | Female | 73 (44.5) | 73 (44.5) | 1.000 |
| Race | White or Caucasian | 102 (62.2) | 102 (62.2) | 1.000 |
| Black or African American | 28 (17.1) | 28 (17.1) | ||
| Asian | 7 (4.3) | 7 (4.3) | ||
| Other | 26 (15.9) | 26 (15.9) | ||
| Unknown | 1 (0.6) | 1 (0.6) | ||
| Body mass index | Mean (standard deviation) | 30.4 (5.9) | 28.2 (5.7) | 0.001 |
| Diabetes | Yes | 94 (57.3) | 94 (57.3) | 1.000 |
| Hypertension | Yes | 42 (25.6) | 42 (25.6) | 1.000 |
| Cardiovascular disease | Yes | 102 (62.2) | 99 (60.4) | 0.821 |
| Lung disease | Yes | 120 (73.2) | 112 (68.3) | 0.396 |
| Cancer type | Hematologic | 129 (78.7) | 129 (78.7) | |
| Solid | 35 | 35 | ||
| Solid tumor types | Bone | 3 (1.8) | 8 (4.9) | 0.157 |
| Breast | 7 (4.3) | 0 | ||
| CNS | 3 (1.8) | 0 | ||
| CRC | 1 (0.6) | 5 (3.0) | ||
| Endocrine | 1 (0.6) | 3 (1.8) | ||
| GI | 2 (1.2) | 2 (1.2) | ||
| GU | 4 (2.4) | 3 (1.8) | ||
| GU, CRC | 0 | 1 (0.6) | ||
| Gyn | 3 (1.8) | 2 (1.2) | ||
| Heme, Breast | 1 (0.6) | |||
| Heme, THN | 1 (0.6) | |||
| HPB | 3 (1.8) | 3 (1.8) | ||
| HPB, CRC | 1 (0.6) | 0 | ||
| SKIN | 2 (1.2) | 2 (1.2) | ||
| History of bone marrow—HSCT‐transplant | Yes | 4 (100.0) | 2 (100.0) | 1.000 |
| Recent chemotherapy | Yes | 108 (65.9) | 113 (68.9) | 0.638 |
| Recent immunosuppressant | Yes | 158 (96.3) | 159 (97.0) | 1.000 |
| Anticoagulation | Yes | 20 (12.2) | 112 (68.3) | <0.001 |
| Antiplatelet therapy | Yes | 110 (67.1) | 143 (87.2) | <0.001 |
Abbreviations: CRC, colorectal cancer; GI, gastrointestinal; Gyn, gynecological; GU, genitourinary; HPB, hepato‐pancreo‐biliary; THN, thoracic head and neck.